Agios Pharmaceuticals
AGIO
74 hedge funds and large institutions have $804M invested in Agios Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 21 reducing their positions, and 7 closing their positions.
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
91% more capital invested
Capital invested by funds: $420M → $804M (+$384M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 21
12% more funds holding
Funds holding: 66 → 74 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$47.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$10.4M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$8.21M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$6.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$10.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.28M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$2.61M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.13M |
| 5 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$1.36M |
AGIO Hedge Fund Activity: Q1 2014 in Review
74 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2014, worth a combined $804M — up 91% from $420M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new AGIO positions and 7 closed out — a net gain of 9 holders — while 30 added to existing stakes and 21 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $47.1M. The largest seller was Bain Capital Public Equity Management, cutting an estimated $10.5M.
- 74 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2014, up from 66 in Q4 2013.
- Funds reported $804M of Agios Pharmaceuticals stock for Q1 2014, up 91% quarter-over-quarter.
- 16 funds opened new Agios Pharmaceuticals positions in Q1 2014 and 7 closed out, a net change of +9 holders.
- The largest Agios Pharmaceuticals buyer in Q1 2014 was Fidelity Investments, an estimated $47.1M added.
- The largest Agios Pharmaceuticals seller in Q1 2014 was Bain Capital Public Equity Management, an estimated $10.5M sold.
Based on aggregated 13F filings for Q1 2014.